NEW YORK (MedscapeWire) Apr 19 — Donepezil (Aricept) isn't just for Alzheimer's anymore. Results of a randomized, placebo-controlled trial presented April 17 at the American Academy of Neurology 54th ...
Phase I and Randomized Phase II Study of Ruxolitinib With Frontline Neoadjuvant Therapy in Advanced Ovarian Cancer: An NRG Oncology Group Study Adult female BCS exposed to ≥4 cycles of adjuvant ...
Postradiotherapy Neck Dissection for Lymph Node–Positive Head and Neck Cancer: The Use of Computed Tomography to Manage the Neck Thirty-four patients received donepezil 5 mg/d for 6 weeks, then 10 ...
When to raise the dose. Results of clinical trials demonstrate that higher doses are associated with better effects. The difference between donepezil 5 mg and 10 mg, galantamine 9 mg and 12 mg, and ...
July 27, 2010 — The US Food and Drug Administration (FDA) has approved donepezil HCl 23-mg tablets (Aricept; Eisai, Inc and Pfizer, Inc) for the once-daily treatment of moderate to severe Alzheimer's ...
Woodcliff Lake, NJ, and New York, July 23, 2010 - Eisai Inc. and Pfizer Inc [NYSE: PFE] announced today that the U.S. Food and Drug Administration (FDA) approved a new once-daily, higher-dose Aricept ...
Authors of a UK study in this week's issue of THE LANCET conclude that the most widely used drugs to treat Alzheimer's disease (AD) have only minimal efficacy, and that an alternative approach for ...
Gurgaon, India, Ranbaxy Pharmaceuticals Canada Inc. (RPCI), a wholly owned subsidiary of Ranbaxy Laboratories Limited (RLL), announced that RPCI received approval on December 24, 2013 to manufacture ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results